作者
Harry LA Janssen, Hendrik W Reesink, Eric J Lawitz, Stefan Zeuzem, Maribel Rodriguez-Torres, Keyur Patel, Adriaan J Van Der Meer, Amy K Patick, Alice Chen, Yi Zhou, Robert Persson, Barney D King, Sakari Kauppinen, Arthur A Levin, Michael R Hodges
发表日期
2013/5/2
期刊
New England Journal of Medicine
卷号
368
期号
18
页码范围
1685-1694
出版商
Massachusetts Medical Society
简介
Background
The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 (miR-122). Miravirsen is a locked nucleic acid–modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function.
Methods
In this phase 2a study at seven international sites, we evaluated the safety and efficacy of miravirsen in 36 patients with chronic HCV genotype 1 infection. The patients were randomly assigned to receive five weekly subcutaneous injections of miravirsen at doses of 3 mg, 5 mg, or 7 mg per kilogram of body weight or placebo over a 29-day period. They were followed until 18 weeks after randomization.
Results
Miravirsen resulted in a dose-dependent reduction in HCV RNA levels that endured beyond the end of active therapy. In the …
引用总数
20132014201520162017201820192020202120222023202412233335034625923522015319616811042
学术搜索中的文章
HLA Janssen, HW Reesink, EJ Lawitz, S Zeuzem… - New England Journal of Medicine, 2013